On February 16, 2021 Epsilogen Ltd, a global leader in the development of novel immunoglobulin E (IgE) antibodies to treat cancer, reported that IgEs and their potential as "a great way for targeting cancer cells for killing" were cited in a Technology Feature article in the leading science journal, Nature (Press release, Epsilogen, FEB 16, 2021, View Source [SID1234575108]). Entitled "Seven technologies to watch in 2021", the article provided views from seven leading researchers from across the life sciences. Alicia Chenoweth, cancer immunologist at King’s College London and co-chair of the 2022 Antibody Biology and Engineering Gordon Research Conference, exemplified IgEs in her section outlining emerging antibody engineering technologies that she believes could have a significant impact on science in the coming year.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Epsilogen is a pioneer of novel modified IgE antibodies, which have great potential to treat solid cancer tumours. The company is progressing its lead product, MOv18 IgE, towards phase I/IIa clinical trials for the treatment of platinum-resistant ovarian cancer. Phase I data showing safety and initial signs of efficacy of MOv18 IgE in these patients was presented at the 2020 AACR (Free AACR Whitepaper) Virtual Annual Meeting in April.

Dr Tim Wilson, Chief Executive Officer of Epsilogen, commented: "We are pleased to see IgE antibodies recognised in a leading scientific journal as one of the most promising emerging technologies across the entire life sciences sector."